Renee Aguiar-Lucander, Calliditas CEO

Cal­lid­i­tas plans to file for full ap­proval for rare kid­ney dis­ease drug fol­low­ing PhI­II da­ta

Cal­lid­i­tas be­lieves Phase III con­fir­ma­to­ry da­ta it re­leased Sun­day for its oral steroid to treat a rare kid­ney dis­ease could be the fi­nal piece need­ed …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.